Coming off a $44.5 million series A financing in late 2016, TCR2 Therapeutics Inc. snagged another $125 million in an oversubscribed series B financing to advance programs using its T-Cell Receptor Fusion Construct (TRuC) platform. (See BioWorld Today, Dec. 9, 2016.)